Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The…
Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy Greenstone Biosciences, a biotechnology company advancing New Approach Methodologies (NAMs) for drug discovery, announced that it has received a Catalyze R61 award from the National…
DXP Enterprises, Inc. Announces Acquisition of Mequipco Ltd. DXP Enterprises, Inc. announced that it has completed the acquisition of Mequipco Ltd. Founded in 1974, Mequipco is headquartered in Calgary, Alberta Canada and operates out of three locations servicing Western Canada including…
Neo7Bioscience & McCullough Foundation Expose 3.5-Year Spike Persistence, Cancer Genomic Integration & mRNA Gene Chaos — Personalized Precision Peptides Restore Critically Injured Patients Neo7Bioscience, a leader in aHI-driven personalized molecular solutions, announced compelling evidence of prolonged SARS-CoV-2 Spike protein persistence…
Lantern Pharma Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine Lantern Pharma Inc. a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and…
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline Glucotrack announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45…
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate Fresenius Kabi, an operating company of Fresenius, announced that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics…
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate Polpharma Biologics International AG announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License…
Feinstein Institutes’ scientists identify the brain’s breathing ‘alarm system’ Beyond automatic breathing reflexes, new research out of Northwell Health’s Feinstein Institutes for Medical Research discovered a brain circuit that keeps track of every inhale and exhale, explaining critical differences in how we perceive,…
Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026 Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association…
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development N-Zyme Biomedical announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of…
Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Cancer Vaccine Candidate ITI-5000 Immunomic Therapeutics, Inc. a clinical-stage biotechnology company and a U.S.-based subsidiary of HLB, announced that the first participant has been dosed in the Phase 1…